Exclusive: Elliott target Gigamon prepares to explore a sale - sources
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street dips on hot inflation data ahead of Nvidia earnings
- Oil rises as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Gigamon (GIMO) PT Raised to $50 at Needham & Company Amid 'Strategic Review'; Worth $50-$55 in a Deal
June 5, 2017 6:18 AM EDTNeedham & Company raised its price target on Gigamon (NYSE: GIMO) to $50.00 (from $34.00) while maintaining a Buy rating following reports over the weekend the company has undertaken an active review of its "strategic options."
"Based on these events and observations, we think the odds... More
